GE Healthcare booth is seen ahead of the 2022 China International Fair for Trade in Services (CIFTIS) at China National Convention Center on August 28, 2022 in Beijing, China.
CareIntellect for Oncology, as the tool is called, will help oncologists get up to speed on a patient’s history and disease progression by quickly showing them the data they need, the company said. GE said it wants to spare oncologists the headache of digging through records so they can focus on caring for their patients.
Health-care data is notoriously difficult to analyze, and as much as 97% of the data produced by hospitals goes unused, according to a Deloitte report. That information is stored across numerous vendors and file formats such as images, lab test results, clinical notes and device readings, which can be extremely taxing for doctors to sort through.
“It’s very time-consuming, very frustrating for these clinicians,” Dr. Taha Kass-Hout, GE HealthCare’s global chief science and technology officer, told CNBC in an interview.
CareIntellect for Oncology will be able to summarize clinical reports and identify when patients are deviating from their treatment plans, Kass-Hout said. The system can flag when a patient misses a lab test, for instance, so that their doctor can determine the best next steps.
“For cancer patients, the treatment journey can last years and involve numerous doctor visits,” he said.
GE HealthCare’s CareIntellect for Oncology
Courtesy of GE HealthCare
CareIntellect for Oncology can also help identify relevant clinical trials that patients might be eligible for, saving oncologists hours of work, said Chelsea Vane, vice president of digital products at GE HealthCare. That process has traditionally required doctors to scroll through a database of available trials, memorize inclusion and exclusion criteria and dig through patient records to determine a good fit, Vane told CNBC.
“What we’ve done is remove that,” she said.
The purpose of the new app is to save oncologists time and effort, but if doctors want to dive into more detail, CareIntellect for Oncology allows them to view the original record that’s referenced, the company said.
GE HealthCare is planning to make CareIntellect for Oncology widely available to U.S. customers in 2025, and it will initially be optimized for prostate and breast cancers. Health organizations such as Tampa General Hospital are already evaluating it, the company said. Since the tool is cloud-based, it will drive recurring revenue for GE HealthCare, Kass-Hout said.
The company is planning to introduce additional apps under the CareIntellect brand in the future, Kass-Hout said. The oncology tool is the first offering, and health-care organizations will be able to easily pick and choose the apps that they want to enable, he added.
GE HealthCare is also hoping to integrate its CareIntellect products with some of the other early stage AI initiatives it teased on Monday.
The company highlighted five new AI products that it is developing, including a collaborative team of AI agents, a tool to predict an aggressive type of breast cancer recurrence, and a tool to flag suspicious mammography scans to radiologists more quickly.
GE HealthCare decided to preview the new tools to give customers an idea of the problems it’s trying to solve, Kass-Hout said. The company will solicit feedback from health-care organizations and work with regulators as necessary, he said.
For instance, GE HealthCare is exploring how a group of AI agents can work together as a team to support doctors through its tool called Health Companion.
The agents in Health Companion will be trained as experts in specific domains, such as radiology, pathology or genomics, and offer insights based on their expertise, Kass-Hout said. The agents could identify whether a specific symptom is a side effect of treatment or a sign of disease progression, for example, and suggest next steps, he added.
Ideally, the tool will give doctors the same kind of support they’d expect from working with a multidisciplinary team, Kass-Hout said. But while consulting a panel of experts can take days or weeks, Health Companion would be available immediately.
“At the moment, it’s an early concept,” he said. “Our aim is to elevate the standard of care and get ahead of the overburden of clinicians trying to take care of their patient.”
Altimeter Capital CEO Brad Gerstner said Thursday that he’s moving out of the “bomb shelter” with Nvidia and into a position of safety, expecting that the chipmaker is positioned to withstand President Donald Trump’s widespread tariffs.
“The growth and the demand for GPUs is off the charts,” he told CNBC’s “Fast Money Halftime Report,” referring to Nvidia’s graphics processing units that are powering the artificial intelligence boom. He said investors just need to listen to commentary from OpenAI, Google and Elon Musk.
President Trump announced an expansive and aggressive “reciprocal tariff” policy in a ceremony at the White House on Wednesday. The plan established a 10% baseline tariff, though many countries like China, Vietnam and Taiwan are subject to steeper rates. The announcement sent stocks tumbling on Thursday, with the tech-heavy Nasdaq down more than 5%, headed for its worst day since 2022.
The big reason Nvidia may be better positioned to withstand Trump’s tariff hikes is because semiconductors are on the list of exceptions, which Gerstner called a “wise exception” due to the importance of AI.
Nvidia’s business has exploded since the release of OpenAI’s ChatGPT in 2022, and annual revenue has more than doubled in each of the past two fiscal years. After a massive rally, Nvidia’s stock price has dropped by more than 20% this year and was down almost 7% on Thursday.
Gerstner is concerned about the potential of a recession due to the tariffs, but is relatively bullish on Nvidia, and said the “negative impact from tariffs will be much less than in other areas.”
He said it’s key for the U.S. to stay competitive in AI. And while the company’s chips are designed domestically, they’re manufactured in Taiwan “because they can’t be fabricated in the U.S.” Higher tariffs would punish companies like Meta and Microsoft, he said.
“We’re in a global race in AI,” Gerstner said. “We can’t hamper our ability to win that race.”
YouTube on Thursday announced new video creation tools for Shorts, its short-form video feed that competes against TikTok.
The features come at a time when TikTok, which is owned by Chinese company ByteDance, is at risk of an effective ban in the U.S. if it’s not sold to an American owner by April 5.
Among the new tools is an updated video editor that allows creators to make precise adjustments and edits, a feature that automatically syncs video cuts to the beat of a song and AI stickers.
The creator tools will become available later this spring, said YouTube, which is owned by Google.
Along with the new features, YouTube last week said it was changing the way view counts are tabulated on Shorts. Under the new guidelines, Shorts views will count the number of times the video is played or replayed with no minimum watch time requirement.
Previously, views were only counted if a video was played for a certain number of seconds. This new tabulation method is similar to how views are counted on TikTok and Meta’s Reels, and will likely inflate view counts.
“We got this feedback from creators that this is what they wanted. It’s a way for them to better understand when their Shorts have been seen,” YouTube Chief Product Officer Johanna Voolich said in a YouTube video. “It’s useful for creators who post across multiple platforms.”
CEO of Meta and Facebook Mark Zuckerberg, Lauren Sanchez, Amazon founder Jeff Bezos, Google CEO Sundar Pichai, and Tesla and SpaceX CEO Elon Musk attend the inauguration ceremony before Donald Trump is sworn in as the 47th U.S. president in the U.S. Capitol Rotunda in Washington, Jan. 20, 2025.
Saul Loeb | Via Reuters
Technology stocks plummeted Thursday after President Donald Trump’s new tariff policies sparked widespread market panic.
Apple led the declines among the so-called “Magnificent Seven” group, dropping nearly 9%. The iPhone maker makes its devices in China and other Asian countries. The stock is on pace for its steepest drop since 2020.
Other megacaps also felt the pressure. Meta Platforms and Amazon fell more than 7% each, while Nvidia and Tesla slumped more than 5%. Nvidia builds its new chips in Taiwan and relies on Mexico for assembling its artificial intelligence systems. Microsoft and Alphabet both fell about 2%.
The drop in technology stocks came amid a broader market selloff spurred by fears of a global trade war after Trump unveiled a blanket 10% tariff on all imported goods and a range of higher duties targeting specific countries after the bell Wednesday. He said the new tariffs would be a “declaration of economic independence” for the U.S.
Companies and countries worldwide have already begun responding to the wide-sweeping policy, which included a 34% tariff on China stacked on a previous 20% tax, a 46% duty on Vietnam and a 20% levy on imports from the European Union.
China’s Ministry of Commerce urged the U.S. to “immediately cancel” the unilateral tariff measures and said it would take “resolute counter-measures.”
The tariffs come on the heels of a rough quarter for the tech-heavy Nasdaq and the worst period for the index since 2022. Stocks across the board have come under pressure over concerns of a weakening U.S. economy. The Nasdaq Composite dropped nearly 5% on Thursday, bringing its year-to-date loss to 13%.
Trump applauded some megacap technology companies for investing money into the U.S. during his speech, calling attention to Apple’s plan to spend $500 billion over the next four years.